Can Blocked Ureters Mean Something Other Than Cancer? Retroperitoneal Fibrosis

Medically reviewed by Dr. Michael Kachur · Frankfurt, Germany·

The scan says mass. It sits behind the abdominal organs, wrapped around the lower aorta, and it has drawn the ureters in, so urine is backing up and the creatinine is climbing. Nobody says cancer out loud. Everybody is thinking it. Yet a plaque of inflamed scar tissue produces that exact picture, and most masses in that position are not tumour. Separating the two is a reading job, not a guess: the shape of the tissue, the direction the ureters moved, the level it starts at and the inflammatory markers all have to be read against each other, which is the kind of reading Healz is built for.

Category
Health Insights
Date
Reading time
11 min
Share

What is actually wrapped around the aorta?

Can Blocked Ureters Mean Something Other Than Cancer? Retroperitoneal Fibrosis

Retroperitoneal fibrosis is not a tumour. It is fibro-inflammatory tissue that surrounds the aorta and the iliac arteries and often traps the ureters running past them, and the idiopathic form is immune mediated (per a nephrology update in Nephrology Dialysis Transplantation, 2021). It is scar with active inflammation, not a growing cell line, which is why the same disease is also called chronic periaortitis, a name that keeps the aorta rather than the ureter at the centre of the problem. It is rare, appears mostly between the fifth and seventh decades of life, and runs two to three times more often in men (NDT, 2021).

The symptoms are unhelpfully ordinary. Lower back, abdominal or flank pain is the usual opening, dull, worse at night and unchanged by position, reported in 38 to 94 percent of patients across series. What brings the diagnosis forward is usually the kidney, with impaired renal function at diagnosis in 33 to 71 percent (NDT, 2021).

Ask Healz.

One chat instead of ten apps. 1M+ rare cases checked. The root cause, not the label. Private.

Why does it look like cancer on the first scan?

Because it is soft tissue where soft tissue should not be, and that description fits several tumours. Lymphoma, sarcoma, carcinoma metastases and carcinoid can all produce a confluent mass in the same compartment. About one third of all retroperitoneal fibrosis is secondary to something else, so other causes have to be excluded before the idiopathic label is accepted (NDT, 2021). A review of lymphoma presenting this way puts malignancy behind roughly 10 percent of cases and states the uncomfortable part plainly: there is no formal difference in imaging between retroperitoneal fibrosis of benign origin and of malignant origin (Cureus, 2021).

The malignant tumour in this space is a different problem. Our piece on retroperitoneal sarcoma is about a solid tumour with a subtype and a grade, where the first operation decides everything after it. This page is about the benign mimic in the same anatomy: inflamed scar, treated with drugs rather than a resection. The two get confused at exactly one moment, the first scan.

How is the distinction actually made?

By pattern, not by a single test. Idiopathic retroperitoneal fibrosis has a signature: a single or confluent mass around the front and sides of a non-aneurysmal distal aorta and the proximal common iliac arteries, without significantly displacing them. Three features travel with it. It deviates the ureters medially, inward, where malignant disease displaces them laterally. It does not infiltrate muscle or bone. It usually starts below the origin of the renal arteries, where malignant forms often extend above that level (all four, NDT, 2021).

The features that break the pattern are its mirror image: an aorta pushed off its axis, tissue growing into muscle or bone, confluent lymph nodes, disease above the renal arteries, or an odd location such as perirenal, pelvic or isolated peri-iliac (NDT, 2021).

Those features exclude malignancy only with moderate certainty, because a degree of overlap exists (NDT, 2021). In one cohort of 41 patients with a typical presentation, 1 patient, 2 percent, had malignancy (NDT, 2021). Typical imaging makes cancer unlikely, not impossible.

Two other inputs help. Most patients have a raised ESR or CRP at presentation (NDT, 2021), which says something is inflamed without saying what, the limit we wrote about in how to read inflammatory markers. FDG-PET is used less to make the diagnosis than to widen the search, finding disease outside the retroperitoneum: other IgG4-related lesions, thoracic aortic involvement or a malignancy (NDT, 2021).

Why is the kidney drained before the diagnosis is settled?

Because an obstructed kidney is losing function on a clock that does not wait for a diagnosis. Where there is acute kidney injury or at least moderate obstructive uropathy, ureteral drainage comes first, with stents or nephrostomies, and medical therapy follows (NDT, 2021). Drainage neither treats the fibrosis nor commits anyone to a diagnosis, which is its value: it buys the kidney time while the question stays open.

Where ureteral involvement is absent or mild, medical therapy alone is often enough. The regimen these authors use is prednisone 1 mg/kg a day for a month, tapered to 10 mg a day over about three months and then withdrawn slowly over roughly six more, and as many as 90 percent respond to prednisone alone (NDT, 2021). Surgical ureterolysis is kept for refractory cases.

End-stage renal disease is rare, under 5 percent in most series, and mortality is 10 percent or less among patients who respond to steroids (NDT, 2021).

When is a biopsy needed, and when is it not?

The nephrology position is that when imaging is typical, the diagnosis is made without a biopsy, and tissue is taken for atypical presentations: features suggesting a metastatic neoplasm, such as a displaced aorta, muscle or bone infiltration or confluent lymphadenopathy, or a picture suggesting Erdheim-Chester disease, such as a perirenal hairy kidney. Routes are CT guided, laparoscopic or open (NDT, 2021).

The counter-position comes from the cases where that went wrong. Authors reporting lymphoma that had been read as idiopathic retroperitoneal fibrosis argue for biopsy before accepting the idiopathic origin and before starting corticosteroids, because steroids can delay the diagnosis, and their own patient was treated with prednisone before the lymphoma was found. Any unexplained retroperitoneal fibrosis, they conclude, should be investigated for malignancy (Cureus, 2021).

Either way, since steroids can shrink a lymphoma enough to muddy a later biopsy, whether tissue is being taken before treatment starts is fair to ask out loud.

What IgG4-related disease changes

Some of this fibrosis is one organ's share of a systemic condition. Among 132 patients with retroperitoneal fibrosis, 47, or 35.6 percent, were classified as IgG4 related and 85 as idiopathic (PLoS One, 2021).

Serum IgG4 does not settle it. It does not reliably distinguish retroperitoneal fibrosis from other inflammatory or neoplastic disorders (NDT, 2021), and a normal level is sometimes seen in exactly this presentation, IgG4-related periaortitis and retroperitoneal fibrosis, while it tends to run high when the kidney itself is involved. Histology carries the most specific features: storiform fibrosis, and obliterative phlebitis, which is common in IgG4-related disease at other sites though rare in the kidney (Modern Rheumatology, 2019).

What a high level does change is where you look next. In a series of 113 patients, 21 percent had a serum IgG4 above 135 mg/dL, and although their presentation and outcomes resembled those with normal levels, they more often had other IgG4-related lesions such as sclerosing pancreatitis or mediastinal fibrosis, so a high level should prompt a search for other involved sites (NDT, 2021). Second-line drugs are kept for people who cannot tolerate steroids or who do not respond to them; mycophenolate and methotrexate are the usual choices, and rituximab is still being explored. Annual imaging follow-up is recommended in IgG4-related disease even when the kidney was not involved at diagnosis (Modern Rheumatology, 2019).

Medication and the other causes worth naming

Drugs implicated include ergot alkaloids, methysergide, beta blockers and dopamine agonists. Other causes are retroperitoneal lymphoma, sarcoma, carcinoma metastases, carcinoids, trauma, radiotherapy, major abdominal surgery, and infections such as tuberculosis or actinomycosis (NDT, 2021). MedlinePlus adds that long-term use of methysergide, ergot alkaloids or dopamine agonists has rarely been linked to the condition, so avoiding those medicines is a way of avoiding it.

This is the one cause with a free fix: stopping the drug is part of the treatment, which nobody finds unless the medication history is read against the scan.

Why follow-up imaging keeps mattering

Because relapse is common and silent. It occurs in about 10 to 50 percent of patients after treatment is stopped, which is why prolonged surveillance and maintenance are often needed (NDT, 2021). A randomised maintenance trial makes the trade visible: relapse at 26 months was 17 percent with prednisone against 50 percent with tamoxifen, but prednisone caused more steroid toxicity (NDT, 2021).

After a stent is removed, frequent urinary tract ultrasound is recommended to catch recurrent hydronephrosis, and PET-CT can guide monitoring and the decision to stop therapy (NDT, 2021).

How Healz reads a periaortic mass as one case

This diagnosis is assembled from documents that only mean something together: the CT report's wording about the aorta and the ureters, the creatinine trend, the ESR and CRP, the serum IgG4, the medication list, and the pathology if tissue was taken. In ordinary care they arrive weeks apart from a radiologist, a urologist, a nephrologist and a lab, and nobody reads them as one case. Healz holds all of it in a single chat instead of scattered across separate tools and logins.

What proves the one place is what sits in it. Frontier AI works the whole file at once, so the imaging wording and the kidney numbers are read against each other rather than in sequence. Healz is equipped with root-cause technology, so it does not stop at the first label. It asks what a rushed visit skips. Did the ureters go inward or outward. Does the tissue reach above the renal arteries. Is there an ergot drug in the medication list. It cross-checks the case against more than a million rare cases, which is how a benign mimic gets named instead of assumed. Healz's memory holds every result you upload, dates it, and turns a periaortic cuff measured twice six months apart into a trend rather than two unrelated scans, which is what relapse looks like before anyone feels it. You can bring a board-certified doctor into the same chat for a second opinion.

Frequently asked questions

Can blocked ureters mean something other than cancer?

Yes. Retroperitoneal fibrosis, an immune-mediated plaque of fibro-inflammatory tissue around the aorta and iliac arteries, traps the ureters and backs urine up the same way. Idiopathic forms are about 70 percent of cases, roughly one third being secondary to something else, including malignancy (NDT, 2021).

How do doctors tell retroperitoneal fibrosis from a tumour?

By the pattern on imaging first, then by tissue if the pattern is wrong. Idiopathic fibrosis wraps a non-aneurysmal distal aorta without displacing it, deviates the ureters inward, spares muscle and bone, and usually starts below the renal arteries; malignant disease tends to do the opposite (NDT, 2021).

Do you always need a biopsy for retroperitoneal fibrosis?

Not always. With typical imaging the nephrology update makes the diagnosis without one, reserving biopsy for atypical presentations (NDT, 2021). Authors reporting lymphoma misread as retroperitoneal fibrosis argue for tissue before corticosteroids begin, because steroids can delay the real diagnosis (Cureus, 2021).

Why is a stent put in before the cause is treated?

Because an obstructed kidney is losing function while the diagnosis is still open. With acute kidney injury or at least moderate obstructive uropathy, drainage comes first and medical therapy follows (NDT, 2021).

Can medication cause retroperitoneal fibrosis?

It can. Ergot alkaloids, methysergide, beta blockers and dopamine agonists are among the drugs implicated (NDT, 2021), and MedlinePlus notes long-term methysergide, ergot alkaloid or dopamine agonist use has rarely been linked to it. Where a drug is the cause, stopping it is part of the treatment.

A mass around the aorta blocking both ureters is one of the few findings where the frightening reading and the likely one are different diseases, and telling them apart means reading everything at once.

Written by Healz Team · Filed under Health Insights

Your health deserves more than guesswork

Get a real investigation, not a symptom list. Root causes found, history remembered, dots connected.

Not a medical provider. Healz.ai is an educational service. Always discuss every decision with your doctor. AI can make mistakes.

© 2026 HealzAI Inc1111B S Governors Ave #92123, Dover, DE 19904, USAMade with for better health